Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adapt Out COVID
NCT04518410Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies, Cytokines & Interferons, Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of bamlanivimab, amubarvimab, romlusevimab, tixagevimab, cilgavimab and 5 more in coronavirus disease 2019 (COVID-19) (12 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: COVID-19 Symptom Duration at Day 28, Quantification of SARS-CoV-2 RNA at Day 14 and 2 more. Started Aug 2020; status: completed.
02
Drugs
bamlanivimabamubarvimabromlusevimabtixagevimabcilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04518410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518410.